Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Lasofoxifene shows promise for women with ESR1-mutated mBC

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence

Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma